Utidelone for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called utidelone for people with advanced solid tumors that have not responded to standard treatments. It may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have one of these cancers: advanced stomach cancer, bile duct cancer, ovarian cancer, esophageal cancer, liver cancer, colorectal cancer, or cervical cancer that has spread or cannot be removed with surgery.
- You must have received at least one standard treatment for your cancer, but no more than 4 prior treatments.
- You must be able to swallow pills and have adequate organ function (kidney, liver, blood).
- You must have a performance status of 0 or 1, meaning you are fully active or able to do light work.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication, utidelone, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum-based chemotherapy. The goal is to see if utidelone can help control the cancer and potentially slow its growth.
This trial tests a new chemotherapy drug called utidelone, given before surgery for early high-risk or locally advanced breast cancer. The goal is to see if this drug can shrink tumors and improve outcomes. It may be a treatment option for people who meet the specific criteria.
This trial tests a combination of two drugs (utidelone and fruquintinib) for ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow the cancer's growth.
This trial compares an oral capsule form of the experimental drug Utidelone with the standard injection form, in people with HER2-negative advanced breast cancer. The goal is to see if the capsule works as well as the injection and is safe to use.
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Hear when a new Gastric Cancer Adenocarcinoma Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.